Heart Doc VIP with Dr. Joel Kahn Episode 481: What's Coming Next for Lipoprotein(a) Treatments
9 snips
Feb 10, 2026 Discussion of a Lancet analysis on statin side effects and surprising placebo-related symptoms. Coverage of a promising oral PCSK9 inhibitor that cuts LDL about 50%. Review of emerging therapies aimed at lowering lipoprotein(a) and a real-world case illustrating treatment choices. Short takes on blood pressure control, muscle and vascular resilience, exercise variety benefits, and anticoagulation after ablation.
AI Snips
Chapters
Transcript
Episode notes
Most Hypertension Patients Miss Targets
- Only about 20% of diagnosed hypertension patients reach <130/80 despite many treatments.
- Regular home monitoring and lifestyle approaches remain essential to improve control.
Reconsider Long-Term Anticoagulation After Ablation
- After successful AFib ablation, consider switching from anticoagulant to aspirin after 12 months if appropriate.
- Discuss MRI follow-up and bleeding risks with your cardiologist before stopping anticoagulation.
Statin Side Effects Largely Limited In Trials
- A Lancet meta-analysis found statins mainly increased diabetes risk, liver enzymes, and some muscle complaints versus placebo.
- Many reported statin symptoms appear also in placebo groups, suggesting a nocebo effect.